Europe’s Clinical Trial System Has Fully Changed: What CTIS Means in 2026

For years, one awkward reality of running a clinical trial across Europe was that the science could be international while much of the administration still felt stubbornly national.

A sponsor planning the same study in several countries could find itself dealing with separate submissions, national authorities, ethics processes and timelines. Europe had the patients, hospitals and scientific expertise for multinational research, but the regulatory route could still make one study feel like several projects stitched together.

CTIS, the Clinical Trials Information System, was supposed to change that.

By 2026, it is no longer accurate to describe CTIS as a new platform waiting to replace the old system. The transition is over. Since 31 January 2025, clinical trials in the EU and EEA have had to operate under the Clinical Trials Regulation and use CTIS.

According to the European Medicines Agency, more than 5,000 clinical trials were moved into the new framework during the three-year transition period.

That sounds like an administrative milestone. In practice, it changes how sponsors, regulators and the public encounter European clinical research.

One front door does not mean one European regulator

The most obvious change is that CTIS gives sponsors a single online route for clinical-trial applications across participating European countries.

Instead of treating every national submission as an almost separate exercise, sponsors can use one environment to submit and manage applications for multinational studies. The system also supports communication during assessment and continues to be used for notifications and trial information after authorisation.

But a single portal should not be mistaken for a single European regulator.

Member States still authorise and oversee clinical trials. National competent authorities and ethics bodies remain involved in assessment and supervision. EMA maintains CTIS, while the European Commission oversees implementation of the Clinical Trials Regulation.

The European Commission states plainly that from 31 January 2025 onward, trials in the EU and EEA must be conducted under the Clinical Trials Regulation using CTIS.

So the system centralises the route more than it centralises the decision-making.

That distinction matters. Sponsors still have to understand national requirements and manage trials across very different healthcare systems. CTIS gives those activities a common regulatory workspace; it does not make Europe institutionally uniform.

Transparency is now part of trial operations

The second change is less visible when an application begins but potentially more important outside regulatory departments: CTIS is also a public database.

Information stored in the system becomes available through the public portal unless it falls within protected categories such as personal data, commercially confidential information or confidential communications between Member States.

That means document preparation is no longer only about satisfying regulators. Parts of the regulatory record can become part of the public record.

The change became more significant when revised transparency rules took effect in June 2024. One of the important differences was the removal of the previous deferral mechanism that allowed publication of some information to be delayed for extended periods.

EMA now explicitly advises sponsors to understand the publication rules before uploading information and documents to CTIS.

For research teams, transparency therefore has to be considered much earlier. What is uploaded, how confidential material is handled and what version of a document enters the system can have consequences beyond the assessment itself.

This is easy to describe as a procedural detail. It is really a change in how closely regulatory operations and public disclosure now sit together.

The public side of CTIS is becoming more useful

CTIS was built primarily as regulatory infrastructure, but its public-facing role has also grown.

In March 2025, EMA launched a clinical-trial map connected to the CTIS public portal. It allows patients and healthcare professionals to search for trials by medical condition and geographic area.

The search uses lay language rather than requiring people to know the terminology normally used in regulatory submissions. Results can also provide trial-site contact details.

That matters because a trial can be technically public and still be difficult for a potential participant to discover.

Traditional registries are good at storing structured information. They are not always good at answering the question a patient actually has: is there a relevant study near me, and who do I contact?

The EMA trial map does not solve recruitment by itself. Eligibility criteria remain complicated, recruitment status can change and participation still requires clinical discussion.

But it makes the underlying research infrastructure more usable by people outside regulatory affairs.

That is a meaningful distinction.

Large regulatory technology projects rarely have a neat point at which implementation ends and everything simply works forever.

CTIS is no exception.

EMA continues to update training material, sponsor guidance and FAQs. Its 2026 support documentation still addresses practical questions around system use, publication rules, personal data and commercially confidential information.

That continuing work is not evidence that the transition failed. It is what happens when thousands of sponsors, regulators, ethics bodies and research organisations begin using the same system every day.

Small workflow issues suddenly matter at scale.

User permissions matter. Document handling matters. Deadlines matter. The way a notification is submitted matters. The point at which a document becomes public matters.

Moving thousands of trials into CTIS was the first test. Making the system predictable enough for routine multinational research is the harder one.

What has actually changed?

CTIS has not made European clinical trials simple, and it was never likely to.

Trials still take place across different hospitals, languages, ethics structures and national health systems. Sponsors still have to deal with complicated science, site operations and regulation. A shared portal cannot remove those realities.

What it can reduce is one important form of fragmentation.

Sponsors now have a common environment for applications and much of the regulatory interaction that follows. Member States have a shared workspace. Trial information is being published through a more transparent public system, and patients have better tools for finding studies.

The success of CTIS will eventually be judged by fairly ordinary questions: whether multinational applications move predictably, whether sponsors can navigate the system without creating new administrative bottlenecks, whether regulators can work efficiently across borders, and whether the information released to the public is genuinely useful.

Europe has completed the formal transition to its common clinical-trials system.

The more interesting phase is happening now: finding out whether a shared digital infrastructure can make a continent-sized research environment work more like one.